2Prof. Dr., Okmeydanı Eğitim ve Araştırma Hastanesi, Göz Kliniği, İstanbul, Türkiye Purpose: To evaluate the effect of serous macular detachment (SMD) on anti-VEGF treatment in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO)
Materials and Methods: 46 eyes of 46 patients with ME due to CRVO were reviewed retrospectively. The patients were divided into two groups according to presence of the subretinal fl uid in optical coherence tomography (OCT): SMD and non-SMD. Both groups were treated with three monthly anti-VEGF (afl ibercept or ranibizumab) injections followed-up in PRN regimen. At baseline and after every injection bestcorrected visual acuity (BCVA), central macular thickness (CMT), anatomical findings were noted from optical coherence tomography (OCT) images and patients? files.
Results: 19 eyes in SMD and 27 eyes in non-SMD groups were studied. The groups were similar in terms of baseline characteristics (p>0.05). Both groups had improvement in BCVA and decrease in CMT during treatment period (p<0.001). Although SMD group had higher BCVA than non-SMD group at all time, this difference was statistically signifi cant only at first and second months (p=0.024 and p=0.023, respectively). The change in BCVA during treatment period was higher in SMD group than non-SMD group (p=0.047). The groups were similar in terms of anatomical gain (p>0.05).
Conclusion: The patients with SMD had higher anatomical gain and BCVA than patients with non-SMD during the first months of the anti- VEGF treatment. SMD has good impact on visual gain in patients with CRVO.
Keywords : Anti-VEGF, central retinal vein occlusion, macular edema, serous macular detachment